Insulin Delivery Systems: Reducing Barriers to Insulin Therapy and Advancing Diabetes Mellitus Treatment

American Journal of Medicine

Volumn 121, Issue 6 SUPPL., 2008, Pages

  Brunton, Stephen ^a  

^a NONE

Author keywords

Barriers to Initiation; Delivery Devices; Insulin pens; Subcutaneous Insulin Infusion

Indexed keywords

HUMAN INSULIN; INSULIN; INSULIN ASPART; INSULIN DERIVATIVE; INSULIN GLULISINE; INSULIN LISPRO; INSULIN ZINC SUSPENSION; ISOPHANE INSULIN; ORAL ANTIDIABETIC AGENT; RECOMBINANT HUMAN INSULIN;

ARTICLE; CLINICAL TRIAL; DEVICE; DIABETES MELLITUS; DRUG DELIVERY SYSTEM; DRUG INFUSION; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; INSULIN TREATMENT; NON INSULIN DEPENDENT DIABETES MELLITUS; PATIENT ATTITUDE; PRIORITY JOURNAL; QUALITY OF LIFE;

DIABETES MELLITUS, TYPE 2; HUMANS; INSULIN INFUSION SYSTEMS;

EID: 44249102520     PISSN: 00029343     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjmed.2008.03.025     Document Type: Article

References (48)

1. Coates P., Ollerton R., Luzio S., et al. A glimpse of the natural history of established type 2 (non-insulin dependent) diabetes mellitus from the spectrum of metabolic and hormonal responses to a mixed meal at the time of diagnosis. Diabetes Res Clin Pract. 26 (1994) 177-197
2. Diabetes Control and Complications Trial (DCCT) Research Group. The effect of intensive treatment of diabetes on the development and progression of long-term complications in insulin-dependent diabetes mellitus. N Engl J Med. 29 (1993) 977-986
3. UK Prospective Diabetes Study (UKPDS) Group. Intensive blood glucose control with sulphonylureas or insulin compared with conventional treatment and risk of complications in patients with type 2 diabetes (UKPD33). Lancet. 352 (1998) 837-853
4. Diabetes Control and Complications Trial/Epidemiology of Diabetes Interventions and Complications (DCCT/EDIC) Study Research Group. Intensive diabetes treatment and cardiovascular disease in patients with type 1 diabetes. N Engl J Med. 353 (2005) 2643-2653
5. Ohkubo Y., Kishikawa H., Araki E., et al. Intensive insulin therapy prevents the progression of diabetic microvascular complications in Japanese patients with non-insulin dependent diabetes mellitus: a randomized prospective 6-year study. Diabetes Res Clin Pract. 28 (1995) 103-117
6. Polonsky W.H., Fisher L., Guzman S., et al. Psychological insulin resistance in patients with type 2 diabetes: the scope of the problem. Diabetes Care. 28 (2005) 2543-2545
7. United Kingdom Prospective Diabetes Study Group (UKPDS). UKPDS 13: Relative efficacy of randomly allocated diet, sulphonylurea, insulin or metformin in patients with newly diagnosed non-insulin dependent diabetes followed for three years. BMJ. 310 (1995) 83-88
8. Peyrot M., Rubin R.R., Lauritzen T., et al. Resistance to insulin therapy among patients and providers. Diabetes Care 28 (2005) 2673-2679
9. Mollema E.D., Snoek F.J., Ader H.J., et al. Insulin-treated diabetes patients with fear of self-injecting or fear of self-testing: psychological comorbidity and general well-being. J Psychosom Res. 51 (2001) 665-672
10. Nir Y., Paz A., Sabo E., and Potasman I. Fear of injections in young adults: prevalence and associations. Am J Trop Med Hyg. 68 (2003) 341-344
11. Korytkowski M. When oral agents fail: practical barriers to starting insulin. Int J Obes. 26 suppl 3 (2002) S1-S7
12. Haque M., Emerson S.H., Dennison C.R., et al. Barriers to initiating insulin therapy in patients with type 2 diabetes mellitus in public-sector primary health care centres in Cape Town. S Afr Med J. 95 (2005) 798-802
13. Koerbel G., and Korytkowski M. Insulin-therapy resistance: another form of insulin resistance in type 2 diabetes. Practical Diabetology 22 (2003) 36-40
14. Leslie C.A., Satin-Rapaport W., Matheson R.N., et al. Psychological insulin resistance: a missed diagnosis?. Diabetes Spectrum 7 (1994) 52-57
15. Tibaldi J. Initiating and intensifying insulin therapy in type 2 diabetes mellitus. Am J Med. 121 suppl 6A (2008) S20-S29
16. Rolla A. Pharmacokinetic and pharmacodynamics advantages of insulin analogues and premixed insulin analogues over human insulins: impact on efficacy and safety. Am J Med. 121 suppl 6A (2008) S9-S19
17. Graff M.R., and McClanahan M.A. Assessment by patients with diabetes mellitus of two insulin pen delivery systems versus a vial and syringe. Clin Ther. 20 (1998) 486-496
18. Da Costa S. A comparison of insulin pen use in the United States and the United Kingdom. Diabetes Educ. 28 (2002) 52-60
19. American Diabetes Association. Insulin delivery. In: American Diabetes Association. Diabetes Forecast: 2007 Resource Guide [ADA Website]. www.diabetes.org/diabetes-forecast/resource-guide.jsp Accessed May 1, 2007
20. Korytkowski M., Bell D., Jacobsen C., and Suwannasari R. A multicenter, randomized, open-label, comparative, two-period crossover trial of preference, efficacy, and safety profiles of a prefilled, disposable pen and conventional vial/syringe for insulin injection in patients with type 1 or 2 diabetes mellitus. Clin Ther. 25 (2003) 2836-2848
21. Venekamp W.J., Kerr L., Dowsett S.A., et al. Functionality and acceptability of a new electronic insulin injection pen with a memory feature. Curr Med Res Opin. 22 (2006) 315-325
22. Asakura T. Comparison of the dosing accuracy of two insulin injection devices. J Drug Assess. 8 (2005) 201-208
23. Clarke A., and Dain M.P. Dose accuracy of a reusable insulin pen using a cartridge system with an integrated plunger mechanism. Exp Opin Drug Deliv. 3 (2006) 677-683
24. Egekvist H., Bjerring P., and Arendt-Nielsen L. Pain and mechanical injury of human skin following needle insertions. Eur J Pain 3 (1999) 41-49
25. Rubin R.R., and Peyrot M. Quality of life, treatment satisfaction, and treatment preference associated with use of a pen device delivering a premixed 70/30 insulin aspart suspension (aspart protamine suspension/soluble aspart) versus alternative treatment strategies. Diabetes Care 27 (2004) 894-903
26. ®: addressing issues of confidence and convenience in insulin delivery. Clin Ther. 27 suppl B (2005) S89-S100
27. Le Floch J.P., Herbreteau C., Lange F., and Perlemuter L. Biological material in needles and cartridges after insulin injection with a pen in diabetic patients. Diabetes Care 21 (1998) 1502-1504
28. Pellissier G., Migueres B., Tarantola A., et al., GERES group. Risk of needlestick injuries by injection pens. J Hosp Infect. 63 (2006) 60-64
29. Del Roio R., and Damiani D. Insulin pump therapy in type 1 diabetes mellitus. J Pediatr. 82 (2006) 249-254
30. Pickup J., Mattock M., and Kerry S. Glycaemic control with continuous subcutaneous insulin infusion compared with intensive insulin injections in patients with type 1 diabetes: meta-analysis of randomised control trials. BMJ. 324 (2002) 705
31. Weissberg-Benchell J., Antisdel-Lomaglio J., and Sheshadri R. Insulin pump therapy: a meta-analysis. Diabetes Care 6 (2003) 1079-1087
32. Doyle E.A., Weinzimer S.A., Steffen A.T., et al. A randomized, prospective trial comparing the efficacy of continuous subcutaneous insulin infusion with multiple daily injections using insulin glargine. Diabetes Care 27 (2004) 1554-1558
33. Usian M.M., Burton D.M., Chertow B.S., and Collins R. Accessibility of insulin pumps for blind and visually impaired people. Diabetes Technol Ther. 6 (2004) 621-634
34. Saudek C.D. Novel forms of insulin delivery. Endocrinol Metab Clin North Am. 26 (1997) 599-610
35. 1c with low risk of hypoglycemia. J Pediatr Endocrinol Metab. 16 (2003) 393-399
36. DeVries J.H., Snook F.J., Kostense P.J., et al., Dutch Insulin Pump Study Group. A randomized trial of continuous subcutaneous insulin infusion and intensive injection therapy in type 1 diabetes for patients with long-standing poor glycemic control. Diabetes Care 25 (2002) 2074-2080
37. Guilhem I., Leguerrier A.M., Lecordier F., et al. Technical risks with subcutaneous insulin infusion. Diabetes Metab. 32 (2006) 279-284
38. Cefalu W.T. Concept, strategies and feasibility of noninvasive insulin delivery. Diabetes Care 27 (2004) 239-246
39. Rosenstock J., Zinman B., Murphy L.J., et al. Inhaled insulin improves glycemic control when substituted for or added to oral combination therapy in type 2 diabetes: a randomized controlled trial. Ann Intern Med. 143 (2005) 549-558
40. Skyler J.S., Cefalu W.T., Kourides I.A., et al. Efficacy of inhaled human insulin in type 1 diabetes mellitus: a randomised proof-of-concept study. Lancet 357 (2001) 331-335
41. Skyler J.S., Weinstock R.S., Raskin P., et al., Inhaled Insulin Phase III Type 1 Diabetes Study Group. Use of inhaled insulin in a basal/bolus insulin regimen in type 1 diabetic subjects: a 6-month, randomized comparative trial. Diabetes Care 28 (2005) 1630-1635
42. Ceglia L., Lau J., and Pittas A.G. Meta-analysis: efficacy and safety of inhaled insulin therapy in adults with diabetes mellitus. Ann Intern Med. 145 (2006) 665-675
43. Gerber R.A., Cappelleri J.C., Kourides I.A., and Gelfand R.A. Treatment satisfaction with inhaled insulin in patients with type 1 diabetes mellitus: a randomized controlled trial. Diabetes Care 24 (2001) 1556-1559
44. Cappelleri J.C., Cefalu W.T., Rosenstock J., et al. Treatment satisfaction in type 2 diabetes: a comparison between an inhaled insulin regimen and a subcutaneous insulin regimen. Clin Ther. 24 (2002) 552-564
45. Laube B. Treating diabetes with aerosolized insulin. Chest 120 (2001) 99-106
46. Himmelmann A., Jendles J., Mellen A., et al. The impact of smoking on inhaled insulin. Diabetes Care 26 (2003) 677-682
47. Stoever J.A., and Palmer J.P. Inhaled insulin and insulin antibodies: a new twist to an old debate. Diabetes Technol Ther. 4 (2002) 157-161
48. Farr S.J., Rowe A.M., Rubsamen R., and Taylor G. Aerosol deposition in the human lung following administration from a microprocessor controlled pressurized metered dose inhaler. Thorax 50 (1995) 639-644